Anadis goes over
Friday, 06 June, 2008
Victorian biotech Anadis (ASX: ANX) has sold over $820,000 worth of new shares to its shareholders under its share purchase plan (SPP), raising over $70,000 more than was intended.
The company, which specialises in polyclonal antibodies, said it had originally only intended to raise $750,000 under the SPP, but because of overwhelming interest decided to sell more, raising $823,000.
The new funds will be used to help fund clinical trials, and ultimately commercialise new products, the company said.
Heart muscle regeneration genes mapped
Researchers have uncovered insights into how stem cells develop and mature into heart muscle...
The cause of 2022's mpox outbreak revealed
Researchers have discovered that the strain of mpox behind the 2022 outbreak was a weakened form...
New gene therapy treats liver disorder in growing children
Researchers have developed a genome-editing approach that repairs a faulty gene directly at its...
